176
Participants
Start Date
September 28, 2021
Primary Completion Date
March 18, 2024
Study Completion Date
March 18, 2024
PXT3003
Patients will be administered PXT3003 twice daily (bid) at 10mL.
PXT3003 placebo
Patients will be administered PXT3003 placebo twice daily (bid) at 10mL.
Peking University Third Hospital, Beijing
Xuanwu Hospital Capital Medical University, Beijing
The First Bethune Hospital of Jilin University, Changchun
The Third Xiangya Hospital of Central South University, Changsha
The First Affiliated Hospital of Fujian Medical University, Fuzhou
Nanfang Hospital Southern Medical University, Guangzhou
The First Affiliated Hospital,Sun Yat-sen University, Guangzhou
The Affiliated Hospital of Guizhou Medical University, Guiyang
The Second Affiliated Hospital Zhejiang University School of Medicine, Hangzhou
The First Affiliated Hospital of Harbin Medical University, Harbin
The First Affiliated Hospital of Anhui Medical University, Hefei
Inner Mongolia People's Hospital, Hohhot
Qilu Hospital of Shandong University, Jinan
The Second Affiliated Hospital of Nanchang University, Nanchang
The Affiliated Hospital of Nanjing University Medical School, Nanjing
Zhongda Hospital Southeast University, Nanjing
Qilu Hospital of Shandong University(Qingdao), Qingdao
Shanghai Jiaotong University School of Medicine Ruijin Hospital, Shanghai
The First Hospital of China Medical University, Shenyang
The Second Hospital of Hebei Medical University, Shijiazhuang
The First Affiliated Hospital of Soochow University, Suzhou
Renmin Hospital of Wuhan University(Hubei General Hospital), Wuhan
The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an
Henan Provincial People's Hospital, Zhengzhou
The First Affiliated Hospital of Zhengzhou University, Zhengzhou
Tasly GeneNet Pharmaceuticals Co., Ltd
INDUSTRY